share_log

Avalo Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer VARKI PAUL

Avalo Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer VARKI PAUL

Avalo Therapeutics | 3:首次持股聲明-高管 VARKI PAUL
美股sec公告 ·  06/25 16:06
Moomoo AI 已提取核心訊息
Paul Varki, the Chief Legal Officer of Avalo Therapeutics, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3 requirements. The document, dated 06/24/2024, indicates that Varki does not beneficially own any non-derivative or derivative securities of the company. The filing was completed on 06/25/2024 and was submitted as an individual filing. This formality is part of the regulatory compliance under Section 16(a) of the Securities Exchange Act of 1934, which mandates reporting by directors, officers, or owners of more than ten percent of a class of the company's equity securities.
Paul Varki, the Chief Legal Officer of Avalo Therapeutics, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3 requirements. The document, dated 06/24/2024, indicates that Varki does not beneficially own any non-derivative or derivative securities of the company. The filing was completed on 06/25/2024 and was submitted as an individual filing. This formality is part of the regulatory compliance under Section 16(a) of the Securities Exchange Act of 1934, which mandates reporting by directors, officers, or owners of more than ten percent of a class of the company's equity securities.
Avalo Therapeutics公司的首席法律官Paul Varki已經根據3表要求向SEC提交了證券利益擁有的初始聲明。該文件日期爲06/24/2024,表明Varki沒有持有該公司的任何非衍生或衍生證券的受益權。提交於06/25/2024並作爲個人提交。此正式流程是證券交易法1934年第16(a)條項下規定的監管合規的一部分,該規定要求董事、高管或持有公司股票某一類超過10%的股東報告。
Avalo Therapeutics公司的首席法律官Paul Varki已經根據3表要求向SEC提交了證券利益擁有的初始聲明。該文件日期爲06/24/2024,表明Varki沒有持有該公司的任何非衍生或衍生證券的受益權。提交於06/25/2024並作爲個人提交。此正式流程是證券交易法1934年第16(a)條項下規定的監管合規的一部分,該規定要求董事、高管或持有公司股票某一類超過10%的股東報告。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息